Triple negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet, treatment failure is commonly observed due to the development of acquired chemoresistance, which remains a clinical challenge for TNBC therapy.
","abstract_html":"<p>Triple negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet, treatment failure is commonly observed due to the development of acquired chemoresistance, which remains a clinical challenge for TNBC therapy.</p>","abstract_has_math":false,"creators":["Deng, Shanshan"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation","degree_discipline":"Pharmaceutical Sciences","degree_department":null,"school":null,"contributors":["Wei Li, PhD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2020,"date_issued":"2020-11-01T07:00:00Z","date_published":"2020-11-01T07:00:00Z","updated_at":"2026-07-24T05:00:45Z","subjects":["metastasis","microtubules","proliferation","TNBC","tubulin inhibitor","Chemical and Pharmacologic Phenomena","Diseases","Medical Pharmacology","Medical Sciences","Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Neoplasms","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://dc.uthsc.edu/dissertations/533","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Wei Li, PhD"]},{"key":"dc:creator","label":"Author","values":["Deng, Shanshan"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2022-11-29T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmaceutical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["metastasis","microtubules","proliferation","TNBC","tubulin inhibitor","Chemical and Pharmacologic Phenomena","Diseases","Medical Pharmacology","Medical Sciences","Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Neoplasms","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://dc.uthsc.edu/dissertations/533"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Triple negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet, treatment failure is commonly observed due to the development of acquired chemoresistance, which remains a clinical challenge for TNBC therapy.
"]},{"key":"dc:title","label":"Title","values":["VERU-111 as an Oral Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer and Evaluation of Novel Tubulin Inhibitors for Cancer Therapy"]}]}],"canonical_facts":{"dc:contributor":["Wei Li, PhD"],"dc:creator":["Deng, Shanshan"],"dc:date.available":["2022-11-29T08:00:00Z"],"dc:description.abstract":["Triple negative breast cancer (TNBC) has aggressive clinical features strongly associated with poorer overall prognosis and higher mortality rates relative to other molecular subtypes. FDA-approved drugs, such as paclitaxel, are effective in treating TNBC. Yet, treatment failure is commonly observed due to the development of acquired chemoresistance, which remains a clinical challenge for TNBC therapy.
"],"dc:identifier":["https://dc.uthsc.edu/dissertations/533"],"dc:subject":["metastasis","microtubules","proliferation","TNBC","tubulin inhibitor","Chemical and Pharmacologic Phenomena","Diseases","Medical Pharmacology","Medical Sciences","Medicinal and Pharmaceutical Chemistry","Medicine and Health Sciences","Neoplasms","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences"],"dc:title":["VERU-111 as an Oral Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer and Evaluation of Novel Tubulin Inhibitors for Cancer Therapy"],"thesis:degree_discipline":["Pharmaceutical Sciences"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T05:00:45Z"}